State Street Corp boosted its position in Flexion Therapeutics, Inc. (NASDAQ:FLXN) by 111.8% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 829,254 shares of the specialty pharmaceutical company’s stock after buying an additional 437,648 shares during the period. State Street Corp’s holdings in Flexion Therapeutics were worth $22,316,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of FLXN. Teachers Advisors LLC boosted its stake in shares of Flexion Therapeutics by 3.1% in the first quarter. Teachers Advisors LLC now owns 44,796 shares of the specialty pharmaceutical company’s stock worth $1,205,000 after buying an additional 1,328 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Flexion Therapeutics by 5.7% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 55,853 shares of the specialty pharmaceutical company’s stock worth $1,503,000 after buying an additional 3,003 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of Flexion Therapeutics by 30.8% in the first quarter. Janney Montgomery Scott LLC now owns 13,575 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 3,200 shares during the last quarter. Swiss National Bank boosted its stake in shares of Flexion Therapeutics by 13.2% in the first quarter. Swiss National Bank now owns 35,911 shares of the specialty pharmaceutical company’s stock worth $966,000 after buying an additional 4,200 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Flexion Therapeutics by 4.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 100,701 shares of the specialty pharmaceutical company’s stock worth $2,710,000 after buying an additional 4,617 shares during the last quarter. 75.43% of the stock is currently owned by institutional investors and hedge funds.

Shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) traded up 2.66% on Thursday, hitting $22.35. The stock had a trading volume of 77,564 shares. The stock’s market cap is $711.31 million. Flexion Therapeutics, Inc. has a 12 month low of $15.44 and a 12 month high of $29.41. The firm has a 50 day moving average of $22.41 and a 200 day moving average of $21.21.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by $0.11. On average, equities analysts forecast that Flexion Therapeutics, Inc. will post ($3.67) earnings per share for the current fiscal year.

WARNING: “State Street Corp Has $22.32 Million Stake in Flexion Therapeutics, Inc. (FLXN)” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/10/state-street-corp-has-22-32-million-stake-in-flexion-therapeutics-inc-flxn.html.

A number of brokerages have recently commented on FLXN. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $44.00 price objective on shares of Flexion Therapeutics in a research note on Thursday. Cantor Fitzgerald set a $40.00 price objective on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 12th. Zacks Investment Research cut shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $35.00 price objective (up previously from $30.00) on shares of Flexion Therapeutics in a research note on Wednesday, July 12th. Finally, ValuEngine raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Flexion Therapeutics presently has a consensus rating of “Buy” and an average target price of $31.10.

In other Flexion Therapeutics news, Director Mark Stejbach acquired 1,580 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The shares were purchased at an average price of $17.02 per share, with a total value of $26,891.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael D. Clayman acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The shares were acquired at an average cost of $17.23 per share, for a total transaction of $86,150.00. Following the acquisition, the insider now directly owns 20,146 shares of the company’s stock, valued at $347,115.58. The disclosure for this purchase can be found here. Corporate insiders own 15.98% of the company’s stock.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics, Inc. (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.